-
Product Insights
NewDry (Atrophic) Macular Degeneration Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Dry (Atrophic) Macular Degeneration Clinical Trials Market Report Overview The dry (atrophic) macular degeneration clinical trial market research report provides an overview of the dry (atrophic) macular degeneration clinical trials scenario. The report provides top-line data relating to the clinical trials on dry (atrophic) macular degeneration. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase,...
-
Product Insights
NewAllergic Rhino-Conjunctivitis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Allergic Rhino-Conjunctivitis Clinical Trials Market Report Overview The Allergic Rhino-Conjunctivitis clinical trial market research report provides an overview of the Allergic Rhino-Conjunctivitis clinical trials scenario. This report provides top-line data relating to the clinical trials on Allergic Rhino-Conjunctivitis and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type....
-
Sector Analysis
NewJuvenile Macular Degeneration (JMD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Juvenile Macular Degeneration (JMD) Marketed and Pipeline Drugs Overview JMD, also called juvenile macular dystrophy, is a group of inherited eye disorders that affects children and young adults, disturbing their central vision. JMD is classified into three major types: Stargardt disease, X-linked retinoschisis (juvenile retinoschisis), and Best vitelliform macular dystrophy (Best’s disease). In the 16MM (Australia, Brazil, China, Canada, France, Germany, India, Italy, Japan, Mexico, Russia, South Africa, South Korea, Spain, UK, and the US), epidemiologists estimate there were around...
-
Product Insights
Wet Macular Degeneration Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Wet Macular Degeneration Clinical Trials Market Report Overview The Wet (Neovascular/Exudative) Macular Degeneration clinical trial market research report provides an overview of the Wet Macular Degeneration Clinical trials scenario. This report provides top-line data relating to the clinical trials on Wet Macular Degeneration and an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points...
-
Product Insights
Age Related Macular Degeneration Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Age-Related Macular Degeneration Clinical Trials Market Report Overview The Age-Related Macular Degeneration clinical trial market research report provides an overview of the Age-Related Macular Degeneration clinical trials scenario. This report provides top-line data relating to the clinical trials on Age-Related Macular Degeneration and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points...
-
Product Insights
Uveitis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Uveitis Clinical Trials Market Report Overview The uveitis clinical trial market research report provides an overview of the uveitis clinical trials scenario. The report provides top-line data relating to the clinical trials on uveitis. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. Key Regions North America,...
-
Product Insights
Choroidal Neovascularization Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Choroidal Neovascularization Clinical Trials Market Report Overview The Choroidal Neovascularization clinical trial market research report provides an overview of the Choroidal Neovascularization Clinical trials scenario. This report provides top-line data relating to the clinical trials on Choroidal Neovascularization and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type....
-
Thematic Analysis
Digital Marketing Trends in Age-Related Macular Degeneration
Digital Marketing Trends in Age-Related Macular Degeneration Report Overview Bayer’s Eylea.us achieved the highest total traffic across age-related macular degeneration (AMD) branded patient sites in the US from May 2022 to April 2023. This was followed by Genentech’s Vabysmo.com and Lucentis.com. Overall, the highest proportion of traffic to top branded patient AMD websites originated from organic sources, followed by direct. Novartis’s Beovu.com had the highest proportion of organic traffic, followed by Lucentis.com. The Digital Marketing Trends in the Age-Related Macular Degeneration...
-
Sector Analysis
Allergic Conjunctivitis (AC) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Allergic Conjunctivitis (AC) Marketed and Pipeline Drugs Report Overview Allergic conjunctivitis (AC) is an inflammatory response of the conjunctiva to an allergen or irritant such as pollen, dust, and mold. It is part of a larger systemic atopic reaction and is usually seasonal, with associated upper respiratory tract symptoms and complaints of redness and swelling of the conjunctiva, with severe itching and increased lacrimation. It has been estimated that that the highest diagnosed prevalence of AC will be in China,...
-
Product Insights
Keratoconjunctivitis Sicca Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Keratoconjunctivitis Sicca Clinical Trials Market Report Overview The Keratoconjunctivitis Sicca (Dry Eye) clinical trial market research report provides an overview of the Keratoconjunctivitis Sicca (Dry Eye) clinical trials scenario. The report provides top-line data relating to the clinical trials on Keratoconjunctivitis Sicca (Dry Eye). It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status,...
-
Product Insights
Glaucoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Glaucoma Clinical Trials Market Report Overview The Glaucoma clinical trial market research report provides an overview of the Glaucoma clinical trials scenario. The report provides top-line data relating to the clinical trials on Glaucoma. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
-
Product Insights
Age Related Macular Degeneration Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Age Related Macular Degeneration Pipeline Drugs Market Report Overview Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in the depreciation of the macula which may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity, etc. Symptoms include the development of blind spots and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy, and medication such as anti-angiogenic drugs. The...
-
Product Insights
Presbyopia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Presbyopia Pipeline Drugs Market Report Overview Presbyopia is an eye condition in which the eye slowly loses the ability to focus quickly on close objects. Presbyopia happens in people as they age. Signs and symptoms include headaches, eyestrain, difficulty reading small print, and fatigue. Risk factors include anemia, diabetes, cardiovascular disease, hyperopia, multiple sclerosis, myasthenia gravis, and eye trauma. The Presbyopia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Presbyopia, complete with analysis by...
-
Product Insights
Graves’ Ophthalmopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Graves’ Ophthalmopathy Pipeline Drugs Market Report Overview Graves’ ophthalmopathy is an autoimmune condition where the thyroid gland mistakenly senses harmful cells and releases antibodies to combat them. Since there are no harmful cells, the released antibodies end up fusing with muscles in the eyes, causing the onset of Graves‘ ophthalmopathy. Symptoms include eye redness, inflammation, eyelid retraction, and weakness. Treatment includes radioiodine therapy, anti-thyroid medications, and thyroid surgery. The Graves’ Opththalmopathy pipeline drugs market research report provides comprehensive information on...
-
Product Insights
Retinitis Pigmentosa (Retinitis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Retinitis Pigmentosa (Retinitis) Pipeline Drugs Market Report Overview Retinitis Pigmentosa (RP) refers to a group of diseases that cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance, and x-linked inheritance. The Retinitis Pigmentosa pipeline drugs market research report provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa, complete with analysis by stage of...
-
Product Insights
Macular Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Macular Edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the retina. Other causes include retinal vein occlusion, side effects of certain medications and certain genetic disorders, such as...
-
Product Insights
Retinal Vein Occlusion Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Retinal Vein Occlusion is a blockage in one of the veins returning blood flow from the retina. Its predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol, and age. The Retinal Vein Occlusion pipeline market research report provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action...
-
Sector Analysis
Glaucoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Glaucoma represents a group of optic neuropathies characterized by the progressive degeneration of retinal ganglion cells (RGCs). It is the leading cause of irreversible vision loss worldwide. The Glaucoma marketed and pipeline drugs market research report provides a data-driven overview of the current and future competitive landscape in Glaucoma therapeutics. This report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing and reimbursement, late-stage pipeline products with phase transition success rate (PTSR), and the likelihood...
-
Product Insights
Allergic Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of Allergic Conjunctivitis include intense itching, puffy eyelids, widened (dilated) vessels in the clear tissue covering the white of the eye, and stringy eye discharge. Its treatment includes antihistamine or anti-inflammatory medications. The Allergic Conjunctivitis pipeline market research report provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action...
-
Product Insights
Cataract Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Cataract is a clouding of the normally clear lens of eye that affects vision. Symptoms include clouded, blurred or dim vision, increasing difficulty with vision at night, fading or yellowing of colors, double vision in a single eye and frequent prescription changes in eye wear. The cataract pipeline drugs market research report provides an analysis of the cataract drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.